StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

Earnings

BioXcel Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$0.54
-$1.50 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BioXcel Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q1 FY2026ended Mar 31, 2026May 15, 2026before the open––-$0.54Release
Q4 FY2025ended Dec 31, 2025Mar 27, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open$98.00K-54.2%-$2.18Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open$120.00K-89.1%-$2.45Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open––-$1.50Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025during market hours––-$3.57Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open$214.00K–-$0.32Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024before the open$1.10M–-$0.21Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Mar 12, 2024before the open–––Release
Q3 FY2023ended Sep 30, 2023Nov 14, 2023before the open–––Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BioXcel Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BioXcel Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BioXcel Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. Results
  6. Update
  7. News
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?